Exclusive Summary

• Backed by US-FDA and PIC/S GMP certifications, enabling seamless access to regulated markets and accelerated registration in emerging markets.
• Benefiting from China's integrated supply chain, it offers significant cost advantages and higher margin potential for international distributors compared to Western suppliers.
• Dedicated high-containment hormone production lines ensure scarce, high-quality capacity, while the hard capsule formulation offers superior thermal stability over traditional softgels.
• Targeting over 175 million infertility patients (ART support) globally and a massive menopausal population (HRT), our ready-for-distribution cooperation helps clients immediately capture an inelastic demand.